Business Context and Reporting Period
Company: Matthews International Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2001
Business Overview: Matthews designs, manufactures, and markets custom-made identification products across three segments: Bronze (memorials, crematories, mausoleums), Graphics Imaging (printing plates, pre-press services), and Marking Products (equipment and consumables for product identification).
Key Financial Metrics (Nine Months Ended June 30, 2001)
| Metric | 2001 (9 Months) | 2000 (9 Months) |
|---|---|---|
| Sales | $204.4 million | $200.9 million |
| Gross Profit | $87.8 million | $89.8 million |
| Gross Margin | 42.9% | 44.7% |
| Operating Profit | $39.7 million | $36.2 million |
| Net Income | $23.6 million | $20.9 million |
| Diluted EPS | $1.51 | $1.32 |
| Operating Cash Flow | $21.0 million | $25.0 million |
| Cash & Equivalents | $22.9 million | $29.2 million (Sep 30, 2000) |
| Total Debt (Current + Long-term) | $45.5 million | $17.4 million (Sep 30, 2000) |
| Current Ratio | 2.0 | 2.0 (Sep 30, 2000) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 1.7% year-over-year, driven by a 9% increase in the Bronze segment (due to mausoleum construction and the York acquisition) and offset by declines in Graphics Imaging (-5%) and Marking Products (-10%).
- Profitability: Net income rose 12.9% to $23.6 million. Operating profit increased 9.6% to $39.7 million. However, gross margin declined to 42.9% from 44.7% due to a shift in product mix toward lower-margin mausoleum construction.
- Special Items: The period included a $7.1 million pre-tax gain from the sale of the Tukaiz interest, partially offset by $6.6 million in special charges (asset impairments, restructuring, and non-recurring expenses).
- Debt Levels: Total debt increased significantly from $17.4 million to $45.5 million, primarily due to a $30 million bank loan utilized to finance the acquisition of The York Group's Commemorative Products business.
- Cash Flow: Operating cash flow decreased to $21.0 million from $25.0 million. Investing activities consumed $44.8 million, largely due to the $45 million York acquisition and other smaller acquisitions.
Guidance, Outlook, and Risks
- Acquisitions:
- Completed: Acquired York's Commemorative Products business for $45 million (May 2001) and a 75% interest in Rudolf Reproflex GmbH for $10.5 million (July 2001).
- Pending: Signed a merger agreement to acquire 100% of The York Group, Inc. for $10 per share (plus up to $1 contingent on cash). Closing is anticipated in Q4 2001, subject to EBITDA targets and shareholder approval.
- Restructuring: Recorded $6.6 million in special charges in Q2, including $4.0 million in asset impairments (goodwill write-downs) and $1.2 million in restructuring costs to improve efficiency in Graphics Imaging and Marking Products.
- Accounting Changes: Evaluating the impact of SFAS No. 142 (Goodwill), which will eliminate goodwill amortization and require periodic impairment testing. Adoption is required by Q1 fiscal 2003 but permitted as early as Q1 fiscal 2002.
- Risks: Management cites risks related to economic conditions, industry consolidation, competitive pricing pressures, and foreign currency fluctuations (which negatively impacted sales by $4.6 million and operating profit by $0.9 million).
Investor Verification Checklist
- York Merger Conditions: Verify if The York Group meets the EBITDA threshold required to close the full merger in Q4 2001.
- Goodwill Impairment: Monitor the impact of the $4.0 million goodwill write-down and future impairment testing under SFAS No. 142.
- Debt Servicing: Assess the impact of the increased debt load ($30M new loan) on interest expenses and liquidity, noting the interest rate is LIBOR + 0.75%.
- Segment Performance: Track the recovery of the Graphics Imaging and Marking Products segments following the divestiture of Tukaiz and recent restructuring efforts.
- Foreign Currency Exposure: Evaluate the company's hedging strategies given the $4.6 million negative impact from currency fluctuations in the first nine months.